2seventy bio, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment
The company harnesses the power of genetics and advanced cellular engineering to create novel therapeutics aimed at addressing unmet medical needs in oncology. By leveraging its proprietary platforms, 2seventy bio works on developing personalized treatment options that target specific tumors and aims to improve patient outcomes through precision medicine. The company's commitment to research and development drives its efforts to bring transformative therapies to market for patients battling various forms of cancer.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb.
BALA CYNWYD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 2seventy bio, Inc. (NASDAQTSVT) to Bristol Myers Squibb for $5.00 per share is fair to 2seventy shareholders.
2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSEBMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025.
2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming TD Cowen 45th Annual Healthcare Conference on March 5, 2025 at 11:10 a.m. ET in Boston, Mass.
Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds.
2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET.
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in clinical trials. European Commission decision expected in two months.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. (“2seventy bio” or “the Company”) (NASDAQTSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/TSVT.
